Australia-based Creso Pharma has inked an agreement with Pharmacare Europe to market and distribute its cannaQIX CBD product in the UK, the companies said in a release.
The deal could also lead to Pharmacare marketing other of Creso’s hemp-derived nutraceuticals products in the UK and other European markets under Pharmacare’s Naturopathica brand, the companies said. Pharmacare has more than 10,000 points of sale in Europe.
Creso announced in January that it would be entering the UK with cannaQIX and 50 nutraceutical products after signing a deal with Precision Healthcare for distribution in UK pharmacies and health food stores.
Pharmacare is a European subsidiary of Australia-based PharmaCare Laboratories that operates in Europe and the Middle East, across pharmacy, retail and online channels.
The UK launch of cannaQIX is planned for October 2018.
